.Attributes Medicine, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Point of view asks for inclusion of people with MASLD and dimension of liver outcomes in cardio-- renal-- metabolic trials, when data suggest mechanistically conceivable benefits and also scientific safety-- and details factors to consider for test style and governing approval.